Natural Killer Index From Hematopoietic Stem Cell Graft

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study Identification, Study Status, Referencesv7
  2. Primary and study completion dates changed from estimate of Jul 2012 to Nov 2013
    • Trial status: Recruiting to Completed
    • Enrollment target: estimated 60 to confirmed 92
    • Site details revised
    v6
  3. Primary and study completion dates: Jul 2011 to Jul 2012v5
  4. Enrollment target: 40 to 60
    • Primary and study completion dates: Jul 2011
    • Start date: Apr 2010 to Apr 2007
    • Study arms: 0 to 3
    v4
  5. Start date: Apr 2007 to Apr 2010v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Apr 2007
    • Study title shortened, about 14 words
    v2
  7. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Numerous studies about the potential role of NK alloreactive during a n hematopoietic stem cells graft are based on genotypical analyses of the KIR receptors and on genotypic incompatibilities between KIR and HLA for couple donor/recipient. There is still a lot of issues non resolved: Are KIR really expressed and how occur their expression during time when hematopoietic reconstitution? Is it depending on HLA of the recipient?If KIR are expressed, what are the mechanisms of alloreactivity of NK cells? Are NK able to lyse tumoral cells? Could alloreactive NK cells constitute a therapeutic tool able to induce tolerance and elimination of leukemia during hematopoietic stem cells grafts?
Trial Details
NCT Number NCT00435864
Lead Sponsor Nantes University Hospital
Conditions
(from sponsor)		 Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia, Chronic Myeloid Leukemia
Related terms Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 92 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov